← Vertex Pharmaceuticals Incorporated (VRTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Vertex Pharmaceuticals Incorporated (VRTX)
Pharmaceutical Preparations · market cap $130.1B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-30
PDUFA
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Vertex Pharmaceuticals (VRTX) is a ~$131B market-cap pharma with 6,100 employees. It reported 2025 revenue of $12.0B and net income of $3.95B, and holds $6.14B in cash with net debt of -$6.14B. Our database lists povetacicept as the lead asset (Phase 3, primary membranous nephropathy), with a PDUFA date of 2026-11-30 for povetacicept in IgA nephropathy, a separate indication. Several other readouts are also on our calendar through April 2027, though most dates are estimates.
The catalyst path
- 2026-11-30PDUFA · Povetaciceptimp 8/10
- 2026-12-23 (est.)Phase 2 · IVAimp 7/10
- 2027-01-25 (est.)Phase 3 · Suzetrigineimp 9/10
- 2027-02-02 (est.)Phase 2 · VX-670imp 7/10
- 2027-03-12 (est.)Phase 2 · VX-264imp 7/10
- 2027-03-25 (est.)Phase 2 · VX-993imp 7/10
- 2027-04-06 (est.)Phase 3 · ELX/TEZ/IVAimp 9/10
- 2027-04-06 (est.)Phase 3 · Suzetrigineimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VX-017 | Phase 3 | Diabetes Mellitus, Type 1 |
| VX-548 | Phase 2 | Acute Pain |
| Lumacaftor | Phase 3 | Cystic Fibrosis |
| VX-661 | Phase 2 | Cystic Fibrosis |
| Cethrin | Phase 2 | Spinal Cord Injury |
| ELX/TEZ/IVA | Phase 3 | Cystic Fibrosis |
| VX-661 plus ivacaftor combination | Phase 3 | Cystic Fibrosis |
| IVA | Phase 3 | Cystic Fibrosis |
| VX-150 | Phase 2 | Osteoarthritis |
| Tezacaftor/Ivacaftor | Phase 3 | Cystic Fibrosis |
| LUM/IVA | Phase 3 | Cystic Fibrosis |
| Ivacaftor | Phase 3 | Cystic Fibrosis |
| VX-702 | Phase 2 | Rheumatoid Arthritis |
| VX-445/TEZ/IVA | Phase 3 | Cystic Fibrosis |
| Inaxaplin | Phase 2 | Proteinuric Kidney Disease |
| VX-880 | Phase 3 | Type 1 Diabetes |
| VX-121 | Phase 2 | Cystic Fibrosis |
| VX-787 | Phase 2 | Influenza Virus |
| VX-222 | Phase 2 | Chronic Hepatitis C Virus |
| VX-993 | Phase 2 | Acute Pain |
Price & technical context
3-month
+4.4%
6-month
+27.3%
12-month
+31.2%
52-wk range
$409.47–$558.88
vs 50-day MA
+4.6%
vs 200-day MA
+13.6%
Realized vol
29.6%
Max drawdown
-29.1%
Daily closes through 2026-11-06. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.